Vaccine maker Vaxcyte, Inc. (PCVX) announced Thursday that the U.S. Food and Drug Administration (FDA) has cleared the Company's adult Investigational New Drug (IND) application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).
MaxCyte, Inc. (LON:MXCT – Get Free Report) shares reached a new 52-week low on Wednesday . The stock traded as low as GBX 245 ($2.99) and last traded at GBX 240 ($2.93), with a volume of 71394 shares traded. The stock had previously closed at GBX 252.50 ($3.08). MaxCyte Stock Performance The company has a […]